Healthy Skepticism Library item: 5141

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Lacasse JR.
Consumer advertising of psychiatric medications biases the public against nonpharmacological treatment.
Ethical Hum Psychol Psychiatry 2005 Fal 01; 7:(3):175-9

Abstract:

In the United States, antidepressant medications are heavily promoted through direct-to-consumer advertising, which is regulated by the Food and Drug Administration (FDA). Advertisements for selective serotonin reuptake inhibitors frequently contain information inconsistent with the scientific evidence on the treatment of depression with antidepressants. The information presented serves to promote the use of antidepressants by biasing the public against nonpharmacological treatment of depression. While the FDA enforces regulations requiring fair and balanced presentation when comparing one medication to another, there appears to be no action taken against pharmaceutical companies that distort scientific evidence in order to disparage nonmedical approaches to depression.

Keywords:
Advertising*/legislation & jurisprudence Advertising*/methods Antidepressive Agents/therapeutic use* Depressive Disorder/etiology Depressive Disorder/therapy* Government Regulation Humans Psychotherapy* Risk Assessment United States United States Food and Drug Administration